Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "A low-middle dose of dexamethasone and heparin seems to be effective in COVID-19 patients, but data regarding A low-middle dose of dexamethasone and heparin's possible efficacy in viral pneumonia caused by other viruses are conflicting." provenance.
- SENTENCE label "A low-middle dose of dexamethasone and heparin seems to be effective in COVID-19 patients, but data regarding A low-middle dose of dexamethasone and heparin's possible efficacy in viral pneumonia caused by other viruses are conflicting." provenance.
- SENTENCE label "A low-middle dose of dexamethasone and heparin seems to be effective in COVID-19 patients, but data regarding A low-middle dose of dexamethasone and heparin's possible efficacy in viral pneumonia caused by other viruses are conflicting." provenance.
- SENTENCE label "A low-middle dose of dexamethasone and heparin seems to be effective in COVID-19 patients, but data regarding A low-middle dose of dexamethasone and heparin's possible efficacy in viral pneumonia caused by other viruses are conflicting." provenance.
- SENTENCE label "A low-middle dose of dexamethasone and heparin seems to be effective in COVID-19 patients, but data regarding A low-middle dose of dexamethasone and heparin's possible efficacy in viral pneumonia caused by other viruses are conflicting." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." provenance.
- SENTENCE label "Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients' subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus standard of care (SOC)." provenance.
- SENTENCE label "Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients' subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus standard of care (SOC)." provenance.
- SENTENCE label "Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients' subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus standard of care (SOC)." provenance.
- SENTENCE label "Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients' subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus standard of care (SOC)." provenance.
- SENTENCE label "Preliminary RECOVERY trial results have shown that dexamethasone reduced death rate in certain patients' subgroups (positive results), whereas both hydroxychloroquine and lopinavir/ritonavir produced no benefit (negative results) versus standard of care (SOC)." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.
- SENTENCE label "dexamethasone (Dex) showed stronger affinity to dexamethasone (Dex)'s theoretical (glucocorticoid) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal/mol; while short hydrogen bond distances were observed in both SARS-CoV-2 main protease (Mpro) and IL-6 when compared to its theoretical (glucocorticoid) receptor." provenance.